NOD2 and cancer: Our observation that MHCII+ monocytes expand in Notch2-deficient mice in steady-state conditions might also be in line with NOD2-dependent inducible monocytes and potentially open new treatment options by modulating monocyte Notch2 signaling in cancer patients.